Huapont Life Sciences Co Ltd
Huapont Life Sciences Co.,Ltd. engages in the medicine, medical care, agrochemicals, new materials, tourism, and other businesses in China and internationally. The company is involved in the production and sale of pharmaceutical preparations and raw materials. It also offers medicines for skin, tuberculosis, anti-infection, respiratory, anti-tumor, and cardiovascular, as well as health management… Read more
Huapont Life Sciences Co Ltd (002004) - Total Assets
Latest total assets as of September 2025: CN¥29.24 Billion CNY
Based on the latest financial reports, Huapont Life Sciences Co Ltd (002004) holds total assets worth CN¥29.24 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Huapont Life Sciences Co Ltd - Total Assets Trend (2001–2024)
This chart illustrates how Huapont Life Sciences Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Huapont Life Sciences Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Huapont Life Sciences Co Ltd's total assets of CN¥29.24 Billion consist of 38.3% current assets and 61.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.2% |
| Accounts Receivable | CN¥3.13 Billion | 10.6% |
| Inventory | CN¥2.25 Billion | 7.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.62 Billion | 5.5% |
| Goodwill | CN¥2.03 Billion | 6.9% |
Asset Composition Trend (2001–2024)
This chart illustrates how Huapont Life Sciences Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Huapont Life Sciences Co Ltd's current assets represent 38.3% of total assets in 2024, a decrease from 64.8% in 2001.
- Cash Position: Cash and equivalents constituted 11.2% of total assets in 2024, down from 17.3% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 10.6% of total assets.
Huapont Life Sciences Co Ltd Competitors by Total Assets
Key competitors of Huapont Life Sciences Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Dongbang Agro
KO:007590
|
Korea | ₩272.67 Billion |
|
Nanjing Red Sun Co Ltd
SHE:000525
|
China | CN¥6.84 Billion |
|
Grand Industrial Holding Co Ltd
SHE:000626
|
China | CN¥8.43 Billion |
|
Sichuan Meifeng Chemical Industry Co Ltd
SHE:000731
|
China | CN¥5.17 Billion |
|
Qinghai Salt Lake Industry Co.Ltd
SHE:000792
|
China | CN¥50.97 Billion |
|
Asia Potash International Investment Guangzhou Co Ltd
SHE:000893
|
China | CN¥19.38 Billion |
|
Hubei Xinyangfeng Fertilizer Co Ltd
SHE:000902
|
China | CN¥19.75 Billion |
|
Sichuan Lutianhua Co Ltd
SHE:000912
|
China | CN¥9.46 Billion |
Huapont Life Sciences Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Huapont Life Sciences Co Ltd generates 0.40x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Huapont Life Sciences Co Ltd is currently not profitable relative to its asset base.
Huapont Life Sciences Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.34 | 1.11 | 0.92 |
| Quick Ratio | 1.10 | 0.89 | 0.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.90 Billion | CN¥ 1.20 Billion | CN¥ -917.78 Million |
Huapont Life Sciences Co Ltd - Advanced Valuation Insights
This section examines the relationship between Huapont Life Sciences Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.09 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -4.2% |
| Total Assets | CN¥29.45 Billion |
| Market Capitalization | $933.86 Million USD |
Valuation Analysis
Below Book Valuation: The market values Huapont Life Sciences Co Ltd's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Huapont Life Sciences Co Ltd's assets decreased by 4.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Huapont Life Sciences Co Ltd (2001–2024)
The table below shows the annual total assets of Huapont Life Sciences Co Ltd from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥29.45 Billion | -4.16% |
| 2023-12-31 | CN¥30.73 Billion | +2.34% |
| 2022-12-31 | CN¥30.02 Billion | -0.07% |
| 2021-12-31 | CN¥30.04 Billion | +6.44% |
| 2020-12-31 | CN¥28.23 Billion | +5.97% |
| 2019-12-31 | CN¥26.64 Billion | +0.32% |
| 2018-12-31 | CN¥26.55 Billion | -8.73% |
| 2017-12-31 | CN¥29.09 Billion | +20.07% |
| 2016-12-31 | CN¥24.23 Billion | +22.92% |
| 2015-12-31 | CN¥19.71 Billion | +45.27% |
| 2014-12-31 | CN¥13.57 Billion | +77.42% |
| 2013-12-31 | CN¥7.65 Billion | +29.13% |
| 2012-12-31 | CN¥5.92 Billion | +41.36% |
| 2011-12-31 | CN¥4.19 Billion | +208.42% |
| 2010-12-31 | CN¥1.36 Billion | +18.84% |
| 2009-12-31 | CN¥1.14 Billion | +0.32% |
| 2008-12-31 | CN¥1.14 Billion | +4.66% |
| 2007-12-31 | CN¥1.09 Billion | +42.29% |
| 2006-12-31 | CN¥765.08 Million | +60.11% |
| 2005-12-31 | CN¥477.85 Million | -0.66% |
| 2004-12-31 | CN¥481.04 Million | +113.10% |
| 2003-12-31 | CN¥225.73 Million | +9.00% |
| 2002-12-31 | CN¥207.09 Million | +55.23% |
| 2001-12-31 | CN¥133.41 Million | -- |